NEWTOWN, PA — KVK Tech, Inc. has achieved a milestone with the successful registration of Lomaira™ (phentermine hydrochloride USP) 8 mg tablets, CIV in Mexico. This development stems from a strategic partnership with Productos Medix S.A. de C.V. (“Medix”), a renowned name in pharmaceutical obesity treatments in Mexico. The agreement grants Medix the rights to manufacture, distribute, and market Lomaira in the country.
Lomaira, a prescription-only appetite suppressant, is intended for short-term use to aid weight reduction in adults with a body mass index (BMI) of 30 or more, or 27 or more if accompanied by conditions like controlled high blood pressure, diabetes, or high cholesterol. BMI is a key measure of body fat based on height and weight. Lomaira is recommended to be used alongside increased physical activity and a reduced-calorie diet.
“According to the WHO, Mexico has the 2nd highest prevalence of Overweight and Obesity worldwide. At Medix, we continue to innovate with solutions to treat the burden of the disease, and its negative impact on the quality of life of people living with Obesity. Our extensive portfolio continues to innovate with options like Lomaira, to support our vision,” said Gerardo de Eguiluz, Senior Director of Business Development at Medix.
“We’re thrilled for Medix to launch Lomaira in Mexico and help tackle the unmet needs in the global obesity epidemic,” said Kiran Vepuri, Vice President of Business Development at KVK Tech. “Obesity is not just an American problem and we aspire to help patients worldwide.”
This registration marks a significant step in addressing obesity in Mexico, leveraging KVK Tech’s pharmaceutical expertise and Medix’s market presence.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.